Capital World Investors Acquires 1,935,876 Shares of Amgen Inc. $AMGN

Capital World Investors raised its stake in Amgen Inc. (NASDAQ:AMGN) by 11.5% during the 3rd quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 18,795,474 shares of the medical research company’s stock after acquiring an additional 1,935,876 shares during the quarter. Amgen comprises 0.7% of Capital World Investors’ holdings, making the stock its 29th largest position. Capital World Investors owned 3.49% of Amgen worth $5,303,578,000 as of its most recent filing with the Securities & Exchange Commission.

Several other hedge funds also recently made changes to their positions in the business. Laurel Wealth Advisors LLC boosted its position in shares of Amgen by 27,765.8% during the 2nd quarter. Laurel Wealth Advisors LLC now owns 6,700,621 shares of the medical research company’s stock worth $1,870,880,000 after acquiring an additional 6,676,575 shares in the last quarter. Norges Bank acquired a new position in shares of Amgen in the second quarter valued at approximately $1,663,726,000. Vanguard Group Inc. raised its stake in shares of Amgen by 1.6% during the second quarter. Vanguard Group Inc. now owns 53,711,570 shares of the medical research company’s stock valued at $14,996,807,000 after acquiring an additional 841,117 shares during the last quarter. Charles Schwab Investment Management Inc. lifted its holdings in Amgen by 5.6% during the 2nd quarter. Charles Schwab Investment Management Inc. now owns 12,893,677 shares of the medical research company’s stock worth $3,600,043,000 after buying an additional 687,735 shares during the period. Finally, Panagora Asset Management Inc. lifted its stake in shares of Amgen by 367.4% in the second quarter. Panagora Asset Management Inc. now owns 490,457 shares of the medical research company’s stock worth $136,940,000 after acquiring an additional 385,517 shares during the period. 76.50% of the stock is owned by institutional investors.

Amgen Stock Performance

Shares of NASDAQ:AMGN opened at $376.97 on Tuesday. The company has a market cap of $203.21 billion, a price-to-earnings ratio of 26.49, a price-to-earnings-growth ratio of 3.67 and a beta of 0.45. Amgen Inc. has a 12 month low of $261.43 and a 12 month high of $391.29. The company has a 50-day moving average price of $354.21 and a 200-day moving average price of $323.38. The company has a current ratio of 1.14, a quick ratio of 0.90 and a debt-to-equity ratio of 5.78.

Amgen (NASDAQ:AMGN) last announced its quarterly earnings results on Tuesday, February 3rd. The medical research company reported $5.29 EPS for the quarter, topping analysts’ consensus estimates of $4.76 by $0.53. The company had revenue of $9.87 billion during the quarter, compared to analyst estimates of $9.46 billion. Amgen had a return on equity of 148.37% and a net margin of 20.98%.The firm’s revenue was up 8.6% on a year-over-year basis. During the same quarter last year, the firm posted $5.31 earnings per share. Amgen has set its FY 2026 guidance at 21.600-23.000 EPS. As a group, equities analysts anticipate that Amgen Inc. will post 20.62 EPS for the current year.

Amgen Announces Dividend

The firm also recently announced a quarterly dividend, which will be paid on Friday, June 5th. Stockholders of record on Friday, May 15th will be issued a dividend of $2.52 per share. This represents a $10.08 dividend on an annualized basis and a dividend yield of 2.7%. The ex-dividend date is Friday, May 15th. Amgen’s payout ratio is 70.84%.

Wall Street Analysts Forecast Growth

AMGN has been the topic of several research analyst reports. Weiss Ratings restated a “buy (b)” rating on shares of Amgen in a research report on Monday, December 29th. Barclays began coverage on Amgen in a report on Friday, February 20th. They issued an “equal weight” rating and a $350.00 target price on the stock. Royal Bank Of Canada boosted their price target on shares of Amgen from $335.00 to $360.00 and gave the stock an “outperform” rating in a report on Wednesday, February 4th. Wells Fargo & Company upped their price target on Amgen from $325.00 to $375.00 and gave the company an “equal weight” rating in a research report on Thursday, February 19th. Finally, Leerink Partners reiterated a “market perform” rating and issued a $355.00 price objective on shares of Amgen in a research note on Thursday. One equities research analyst has rated the stock with a Strong Buy rating, fourteen have assigned a Buy rating, twelve have issued a Hold rating and two have given a Sell rating to the company’s stock. Based on data from MarketBeat.com, Amgen currently has an average rating of “Hold” and a consensus target price of $354.17.

Amgen Profile

Amgen Inc (NASDAQ: AMGN) is a global biotechnology company founded in 1980 and headquartered in Thousand Oaks, California. The company focuses on discovering, developing, manufacturing and delivering human therapeutics that address serious illnesses. Amgen’s work centers on biologic medicines derived from cellular and molecular biology, with an emphasis on translating advances in human genetics and protein science into therapies for patients.

Amgen’s commercial portfolio has historically included biologics used in oncology, supportive care, nephrology, bone health and cardiovascular disease.